A multicenter retrospective study for the relationship between tumor burden and the eligibility of upfront therapy in patients with castration naive prostate cancer
Main Authors: | H. Iwamura, S. Hatakeyama, S. Narita, M. Takahashi, T. Sakurai, S. Kawamura, S. Hoshi, M. Ishida, T. Kawaguchi, S. Ishidoya, J. Shimoda, H. Sato, I. Hamano, T. Okamoto, K. Mitsuzuka, A. Ito, N. Tsuchiya, Y. Arai, T. Habuchi, C. Ohyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-07-01
|
Series: | European Urology Open Science |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168320331748 |
Similar Items
-
Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
by: Teppei Okamoto, et al.
Published: (2021-05-01) -
Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy
by: Shintaro Narita, et al.
Published: (2019-11-01) -
Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
by: Itsuto Hamano, et al.
Published: (2020-07-01) -
Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer
by: S. Hatakeyama, et al.
Published: (2020-07-01) -
Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
by: Benjamin L Maughan, et al.
Published: (2014-12-01)